Abstract
Autophagy and apoptosis are two well-controlled mechanisms regulating cell fate. An understanding of decision-making between these two pathways is in its infancy. Monoamine oxidase A (MAOA) is a mitochondrial enzyme that is well-known in psychiatric research. Emerging reports showed that overexpression MAOA is associated with prostate cancer (PCa). Here, we show that MAOA is involved in mediating neuroendocrine differentiation of PCa cells, a feature associated with hormone-refractory PCa (HRPC), a lethal type of disease. Following recent reports showing that NED of PCa requires down-regulation of repressor element-1 silencing transcription factor (REST) and activation of autophagy; we observe that MAOA is a novel direct target gene of REST. Reactive oxygen species (ROS) produced by overexpressed MAOA plays an essential role in inhibiting apoptosis and activating autophagy in NED PCa cells. MAOA inhibitors significantly reduced NED and autophagy activation of PCa cells. Our results here show MAOA as a new decision-maker for activating autophagy and MAOA inhibitors may be useful as a potential therapy for neuroendocrine tumors.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Androgen Antagonists / pharmacology
-
Androgen Antagonists / therapeutic use
-
Antineoplastic Agents, Hormonal / pharmacology
-
Antineoplastic Agents, Hormonal / therapeutic use
-
Apoptosis* / drug effects
-
Autophagy* / drug effects
-
Biomarkers
-
Carcinoma, Neuroendocrine / drug therapy
-
Carcinoma, Neuroendocrine / genetics
-
Carcinoma, Neuroendocrine / metabolism*
-
Carcinoma, Neuroendocrine / pathology
-
Cell Line, Tumor
-
Drug Resistance, Neoplasm*
-
Enzyme Activation
-
Gene Expression Regulation, Neoplastic / drug effects
-
Gene Knockdown Techniques
-
Humans
-
Male
-
Mitophagy
-
Models, Biological
-
Monoamine Oxidase / genetics
-
Monoamine Oxidase / metabolism*
-
Monoamine Oxidase Inhibitors / pharmacology
-
Monoamine Oxidase Inhibitors / therapeutic use
-
Neoplasm Grading
-
Promoter Regions, Genetic
-
Prostatic Neoplasms / drug therapy
-
Prostatic Neoplasms / genetics
-
Prostatic Neoplasms / metabolism*
-
Prostatic Neoplasms / pathology
-
Protein Binding
-
Reactive Oxygen Species / metabolism
-
Repressor Proteins / metabolism
Substances
-
Androgen Antagonists
-
Antineoplastic Agents, Hormonal
-
Biomarkers
-
Monoamine Oxidase Inhibitors
-
RE1-silencing transcription factor
-
Reactive Oxygen Species
-
Repressor Proteins
-
Monoamine Oxidase